The aim of this study was to evaluate the efficacy of surgical resection of oral tongue cancer (OTC) pulmonary metastases. Between 1977 and 2003, 23 OTC patients who developed 1-3 pulmonary metastases underwent metastasectomy. There were 14 men and nine women with a median age at the time of first metastasectomy of 56 years. All patients had advanced squamous cell OTC with synchronous or metachronous regional lymph node metastases. The median tumor-free interval after the last OTC treatment was 12 months. Five patients underwent pneumonectomy, three bilobectomy, 13 lobectomy, and two wedge resection. Two patients underwent a second pulmonary metastasectomy. One patient continues to survive, without recurrence 19 years after metastasectomy. Another patient was alive with disease at 24 months after metastasectomy but was lost to follow-up. Twenty-two out of 23 patients developed systemic metastases. The median interval to systemic recurrence after lung resection was 4.1 months, and 21 out of 23 patients died of OTC (median, 9.5 months) after metastasectomy. Most patients who underwent pulmonary metastasectomy died of the disease within two years of metastasectomy. Even for patients with a solitary metastasis, surgical metastasectomy is not a recommended treatment option.
Introduction
The lung is the most frequent site of metastases from head and neck squamous cell carcinomas w1x, and this is also true for oral tongue cancers (OTCs). Lung resection for a solitary metastasis from head and neck squamous cell carcinoma has been reported as a valid treatment option w2-4x. However, its role in OTC patients has not been clarified. The anterior two-thirds of the tongue in the oral cavity (oral tongue) and the posterior third in the oropharynx (base of tongue) arise from separate branchial arches, and have separate venous and lymphatic drainages w5x. Because of the embryological and anatomical differences, cancers arising in the oral tongue and those in the base of tongue behave and are treated differently. We reviewed our experiences in OTC patients who underwent lung resection, to determine the efficacy of pulmonary metastases resection.
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E-mail address: tmochizu@hmedc.or.jp (T. Mochizuki). May 1977 to April 2003 consecutive patients underwent resection of pulmonary metastases from primary OTC in the thoracic oncology departments of two hospitals (the National Cancer Center Hospital East, Chiba, and the Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan). Demographic, perioperative, pathological, and survival data were retrospectively reviewed. Data collection and analysis were approved and the need for obtaining informed consent from each patient was waived by the institutional review boards of both hospitals in October 2006.
Materials and methods

From
Following primary OTC treatment, patients were followed on an outpatient basis every 3-6 months. Each follow-up visit included a physical examination, chest roentgenogram, and blood examination. If abnormal findings suggestive of recurrence were obtained, further re-staging work-up was performed including whole body computed tomography, brain magnetic resonance imaging, and bone scintigram. Fluorine-18-2-fluoro-D-glucose positron emission tomography was performed for selected patients. To be considered for metastasectomy, the primary OTC had to be controlled, there could be no recurrences other than pulmonary metastases, and the patients had to be able to withstand lung resection. The number of nodules or bilaterality was not an exclusion criterion. We performed wedge resection when feasible, but chose extended resection when a metastatic tumor was )3.0 cm, located in the pulmonary hilum, or multiple nodules were found in the same lobe. We reviewed medical records to determine tumor differentiation grade, based on the World Health Organization (WHO) classification for cell types w6x. The pathological stage of OTC at initial presentation was determined based on the TNM classification of the International Union Against Cancer (UICC) w7x.
Survivals were calculated by the Kaplan-Meier method. Zero time was the date of the first metastasectomy, and the terminal event was defined as death due to any cause (overall survival), or as recurrence, identified by serial imaging or biopsy (disease-free survival). An observation was censored at the last follow-up when the patient was alive or lost to follow-up. All statistical analyses were performed using a software package (SPSS, release 11.0; SPSS Inc, Chicago, IL, USA).
Results
Patient characteristics of the 23 patients are summarized in Table 1 . There were 14 men and nine women (maley female ratio, 1.6:1). The median age at the first treatment was 53 years (range, 26-71 years). In all patients the primary disease were in stage II or higher. The median age at the time of pulmonary metastasectomy was 56 years (range, 28-72 years). Thirteen patients (11 men and two women) had a history of smoking, and the median smoking index was 35 pack-years. The remaining three male and seven female patients were non-smokers. All pulmonary metastases were found by outpatient follow-up examinations. The earliest pulmonary metastasis was detected one month after the initial OTC treatment. The median tumorfree interval after the last OTC treatment was 12 months, with a range of 0-60 months. The metastases arose in the right lung in 16 patients and in the left in seven and all were single-sided.
A total of 28 pulmonary metastatic nodules were resected. In two patients, two nodules were resected, and in two patients, three nodules were resected. At the time of the first metastasectomy, 20 patients had a solitary nodule, one had two, and one had three. One patient, who had two nodules at the first metastasectomy underwent a second thoracotomy to resect a new nodule. The average size of the pulmonary metastases was 3.9 cm (range, 1.3-6.0 cm).
Five patients underwent pneumonectomy, three bilobectomy, 13 lobectomy, and two wedge resection. Fifteen patients underwent ipsilateral mediastinal lymph node dissection, and three hilar node dissection, and one lymph node sampling. Metastasectomy was incomplete in seven patients (30%), because of positive resection margins (four patients), pleural dissemination (two patients), or metastatic lymph nodes (one patient). Of the 19 patients who underwent lymphadenectomy, nine (47%) had lymph node metastasis in the mediastinum, and two (11%) in the hilum. Resected nodules were pathologically confirmed to be compatible with pulmonary OTC metastases and were composed of squamous cell carcinoma with a variable degree of keratinization. Chemotherapy details in two patients were not available, but 10 (48%) among the remaining 21 patients underwent systemic chemotherapy consisting of various regimens before andyor after lung resection.
Within 17 months after lung resection, 22 of the 23 patients developed recurrence: five in the lung, four in the pleural cavity, 12 in the bone, one in the brain, three in the liver, two in the cervical lymph node, and three in the mediastinal lymph node (nine in multiple sites), and unknown in four patients. Twenty of these patients developed recurrence within a year after lung resection (Fig.  1) . Fig. 2 . Overall survival curve after first metastasectomy in 23 patients. The median survival time was 9.5 months, and one-, two-, and three-year survival rates were 30%, 13% and 7%, respectively. Fig. 3 . Overall survival after first metastasectomy in 20 solitary pulmonary metastasis patients. The median survival time was 8.8 months, and one-, two-, and three-year survival rates were 30%, 15% and 8%, respectively.
One patient had no evidence of recurrence ;19 years after metastasectomy, and another patient was alive with pulmonary metastases at 24 months but was lost to followup.
The overall survival rates after the first metastasectomy were 30% at one year, 13% at two years, and 7% at three years. The median survival time of the 21 patients who died of OTC was 9.5 months (range, 1-26 months) after the first metastasectomy (Fig. 2) . Even in 20 patients whose metastasis was solitary at the first metastasectomy, the one-, two-, and three-year survival rates were 30%, 15%, and 8%, respectively (Fig. 3 ). There were no significant differences in number or size of pulmonary nodules, disease-free interval, or survival time between patient groups categorized by TNM classification of primary OTC.
The median tumor sizes, positive mediastinal node rates, and median survival times after metastasectomy were 4.5 cm (range, 1.4-6.0 cm), 71%, and 3.1 months (1.4-229 months) in the patients who underwent metastasectomy in the 1980s, and 3.5 cm (1.3-5.5 cm), 56%, and 9.0 months (2.7-26 months) in the 1990s and thereafter. There were no statistical differences in metastatic tumor size, node positive rate, and survival time between these patient groups (Ps0.31, 0.63, and 0.41, respectively). The median survival time was 3.1 months (range, 1.4-12.4 months) for eight bilobectomy or pneumonectomy patients, and was significantly -9.5 months (2.8-230 months) for 15 wedge resection or lobectomy patients (Ps0.02). Even among the wedge resection or lobectomy patients, however, 80% died within 1.5 years after resection. The median survival times were 9.5 months in the patients with node metastases, and 7.5 months without metastases, respectively. There was no statistical difference (Ps0.14).
Discussion
Advances in anesthesia and surgical procedures have enabled extensive treatment including lung resection in pulmonary metastases patients. Pulmonary metastasectomy criteria were first proposed by Thomford et al. in 1965 , and were modified by McCormack et al. as follows: (1) primary site controlled or controllable; (2) no extrapulmonary metastatic sites demonstrable; (3) good surgical risk; and (4) no effective treatment available by nonsurgical means w8x. These criteria have been commonly accepted for the past four decades. At our hospitals, we have actively pursued pulmonary metastasectomy with the following criteria: (1) no metastatic foci outside the lungs; (2) lung resection is tolerable; (3) a good postoperative quality of life is expected; (4) the primary focus is controlled; and (5) complete resection is expected.
Lung resection for a solitary metastasis from head and neck squamous cell carcinoma has been reported as a valid treatment option. Liu et al. analyzed 83 patients with pulmonary metastases from head and neck cancers and reported surgical resection of squamous cell carcinoma metastases resulted in long-term survival with a 32% fiveyear survival rate w2x. Mazer et al. based on 44 squamous cell carcinoma metastases patient analysis, reported an overall five-year survival rate of 43% w4x. Finley et al. compared 54 head and neck squamous cell carcinoma patients who did or did not undergo resection of their pulmonary metastases, and estimated the five-year survival rates of the 18 patients in surgical group and of the remainder in non-surgical group as 29% and 5%, respectively w3x.
To our knowledge, however, there have been no reports on surgical resection only for OTC pulmonary metastases. This study on OTC pulmonary metastases showed outcomes were dismal even in a patient with solitary metastasis. Only a few patients survived more than two years. Despite imaging technique progresses, there were no significant differences in metastatic tumor size, node positive rate, and survival time between patients who underwent metastasectomy in the 1980s and those in the 1990s and on. These findings suggest the poor outcomes were not due to poor pre-metastasectomy staging but due to the aggressive nature of OTC pulmonary metastases. The median survival time in bilobectomy or pneumonectomy patients was significantly shorter than in 15 wedge resection or lobectomy patients. Surgical invasiveness may have played a role in the poorer prognosis. Even among the wedge resection or lobectomy patients, however, 80% died within 1.5 years after resection. Although the median survival time in the patients with node metastasis was shorter than in those without node metastasis, there was no statistical difference. This fact suggests node metastasis did not have a strong impact on outcome. We think OTCs biological aggressiveness had more impact on the poor outcome. We have to conclude that OTC pulmonary metastases resection is of little efficacy.
However, it can be difficult to differentiate OTC pulmonary metastases from primary pulmonary squamous cell cancers. OTC patients are often heavy smokers and are at high-risk for primary pulmonary squamous cell carcinoma w9x. The lifetime incidence of a second primary lung cancer in patients with head and neck cancer has been reported to be 3.3%-5.5% w10, 11x. When multiple pulmonary nodules are found in patients after primary OTC treatment, the reasonable and mostly correct diagnosis is OTC metastases. If a solitary nodule is found, however, it can either be an OTC metastasis or primary lung cancer.
Metastatic squamous cell OTC and primary pulmonary squamous cell carcinoma can be distinguished based on histological disparity, but there are no absolute distinguishing criteria. Because the primary OTC in this series were advanced, we diagnosed the pulmonary lesions as metastases unless there was apparent morphological dissimilarity between the primary tumor and pulmonary lesions. Differential diagnosis can be difficult even in resected specimens, and even more so based on small preoperative biopsy specimens. In order not to miss the possibility of curative surgical resection opportunity for primary lung cancer patients, resection may be indicated in patients with a solitary lung nodule after curative OTC treatment.
One other reason pulmonary metastasectomy was considered to be an option was because there were no effective non-surgical means available w8x. Argiris et al. reported that only a small percentage of patients with recurrent or metastatic head and neck carcinoma can achieve long-term survival after systemic chemotherapy and that a primary hypopharyngeal or oral cavity location was a significant unfavorable prognostic factor w12x. Chemotherapy seems to be an invalid option for OTC metastases patients. As we encountered one long-term survivor after metastasectomy, we may not have to completely exclude surgical resection from treatment options for OTC pulmonary metastases patients.
In conclusion, most patients who underwent OTC pulmonary metastasectomy died of the disease within two years. Even for patients with a solitary metastasis limited to the lung, surgical resection for OTC pulmonary metastases is not a recommended treatment option.
